46.JPG)
Global RNA-based Therapeutics Market is valued at USD 12.4 Billion in 2024 and is predicted to reach USD 22.6 Billion by the year 2034 at a 6.5% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
RNA-based therapeutics is a moderately new class of treatment representing significant potential and growth for the treatment of severe and rare diseases. RNA-based therapeutics are gaining significance for several disease targets, such as genetic disorders, HIV, cancer, etc. The growing prevalence of chronic diseases and lack of proper treatment is generating high demand for the development of RNA-based therapeutics. For instance, according to WHO, cancer ranked number two as a cause of death, and about 9.6 million deaths occurred in 2018. Moreover, the rising prevalence of genetic diseases, hematological disorders are generating the global demand for RNA-based therapeutics. Moreover, advancements and development of promising technologies such as SMaRT technology, antisense technology, and RNAi interference technology are expected to generate immense opportunities for the growth of the market in the coming years.
The strong base on ongoing studies for RNA-based therapeutics and the presence of a large number of players investing in the market is estimated to propel the growth of the market significantly over the estimated timeframe. In July 2018, about 320 ongoing clinical studies for RNA-based therapeutics were registered. The introduction of these potential therapies in the coming years is expected to significantly boost the market's overall growth. However, challenges connected with the commercialization of RNA-based therapies such as drug delivery and toxicity may substantially hamper the market growth. Moreover, the high cost of development may hinder the growth of the market. The lack of substitute treatment selections for rare diseases further enhancing the demand for RNA-based therapeutics globally. Additionally, a growing focus of legislative bodies on evolving reimbursement policies is fueling the development of RNA’s molecules process.
The Global RNA-Based Therapeutics Market is segmented based on product, type, indication and end-user. By Product segment, the market is divided into Vaccines and Drugs. Whereas, By Type, the market is categorized into mRNA Therapeutics, RNA Interference (RNAi) Therapeutics, Antisense Oligonucleotide (ASO) Therapeutics, RNA Aptamer, and Other Therapeutics. The segmentation includes Indication segment which is further classified into Infectious Diseases, Rare Genetic Diseases/Hereditary Diseases, Oncology, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), and Others. The End User segment comprises Hospitals and Clinics, Research Settings.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 12.4 Billion |
|
Revenue Forecast In 2034 |
USD 22.6 Billion |
|
Growth Rate CAGR |
CAGR of 6.5% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Product, Type, Indication, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South Korea; South East Asia |
|
Competitive Landscape |
Akcea Therapeutics Inc, Biogen Inc., Noxxon Pharma, Ophthotech Corporation, Olix Pharmaceuticals, GlaxoSmithKline Plc, Sanofi S.A, Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Benitec Biopharma Ltd, Acuitas Therapeutics, Arbutus Biopharma, Silence Therapeutics Plc, Enzon Pharmaceuticals Inc, Bio-Path Holdings Inc., Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.), Antisense Therapeutics Ltd., Gene Signal, Gradalis, iCo Therapeutics, Lorus Therapeutics (Aptose Biosciences), miRagen Therapeutics, Mirna Therapeutics Inc, Marina Biotech, OncoGeneX Pharmaceuticals, Quark Pharmaceuticals, Pharmaxis Ltd, Rexahn Pharmaceuticals, Regulus Therapeutics, Rxi Pharmaceuticals, Santaris Pharma A/S (Roche), Sarepta Therapeutics, Sirnaomics Inc., and Dicerna Pharmaceuticals |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global RNA- based Therapeutics Market Snapshot
Chapter 4. Global RNA- based Therapeutics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: by Product Estimates & Trend Analysis
5.1. by Product & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product:
5.2.1. Vaccines
5.2.2. Drugs
Chapter 6. Market Segmentation 2: by Type Estimates & Trend Analysis
6.1. by Type & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type:
6.2.1. mRNA Therapeutics
6.2.2. RNA Interference (RNAi) Therapeutics
6.2.3. Antisense Oligonucleotide (ASO) Therapeutics
6.2.4. RNA Aptamer
6.2.5. Other Therapeutics
Chapter 7. Market Segmentation 3: by Indication Estimates & Trend Analysis
7.1. by Indication & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Indication:
7.2.1. Infectious Diseases
7.2.2. Rare Genetic Diseases/Hereditary Diseases
7.2.3. Oncology
7.2.4. Ophthalmology
7.2.5. Hematological Disorders
7.2.6. Acute Hepatic Porphyria (AHP)
7.2.7. Others
Chapter 8. Market Segmentation 4: by End User Estimates & Trend Analysis
8.1. by End User & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by End User:
8.2.1. Hospitals and Clinics
8.2.2. Research Settings
Chapter 9. RNA- based Therapeutics Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.1.2. North America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.1.3. North America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.1.4. North America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.1.5. North America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.2. Europe
9.2.1. Europe RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.2.2. Europe RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.2.3. Europe RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.2.4. Europe RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.2.5. Europe RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.3. Asia Pacific
9.3.1. Asia Pacific RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.3.2. Asia Pacific RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.3.3. Asia-Pacific RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.3.4. Asia-Pacific RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.3.5. Asia Pacific RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.4. Latin America
9.4.1. Latin America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.4.2. Latin America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.4.3. Latin America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.4.4. Latin America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.4.5. Latin America RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
9.5. Middle East & Africa
9.5.1. Middle East & Africa RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
9.5.2. Middle East & Africa RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
9.5.3. Middle East & Africa RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by Indication, 2021-2034
9.5.4. Middle East & Africa RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by End User, 2021-2034
9.5.5. Middle East & Africa RNA- based Therapeutics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Akcea Therapeutics Inc,
10.2.2. Biogen Inc.,
10.2.3. Noxxon Pharma,
10.2.4. Ophthotech Corporation,
10.2.5. Olix Pharmaceuticals,
10.2.6. GlaxoSmithKline Plc,
10.2.7. Sanofi S.A,
10.2.8. Alnylam Pharmaceuticals,
10.2.9. Ionis Pharmaceuticals,
10.2.10. Benitec Biopharma Ltd,
10.2.11. Acuitas Therapeutics,
10.2.12. Arbutus Biopharma,
10.2.13. Silence Therapeutics Plc,
10.2.14. Enzon Pharmaceuticals Inc,
10.2.15. Bio-Path Holdings Inc.,
10.2.16. Calando Pharmaceuticals (Arrowhead Pharmaceuticals, Inc.),
10.2.17. Antisense Therapeutics Ltd.,
10.2.18. Gene Signal,
10.2.19. Gradalis,
10.2.20. iCo Therapeutics,
10.2.21. Lorus Therapeutics (Aptose Biosciences),
10.2.22. miRagen Therapeutics,
Global RNA-based Therapeutics Market by Product
Global RNA-based Therapeutics Market Based on Type
Global RNA-based Therapeutics Market Based on Indication
Global RNA-based Therapeutics Market Based on End-User
Global RNA-based Therapeutics Market Based on Region
Europe RNA-based Therapeutics Market by Country
North America RNA-based Therapeutics Market by Country
Asia Pacific RNA-based Therapeutics Market by Country
Latin America RNA-based Therapeutics Market by Country
Middle East & Africa RNA-based Therapeutics Market by Country
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
